公开(公告)号：US11673953B2

公开(公告)日：2023-06-13

申请号：US16802822

申请日：2020-02-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi Zhang ,  Thomas John Van Blarcom ,  Siler Panowski ,  Silvia K. Tacheva-Grigorova ,  Barbra Johnson Sasu

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/2887 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/70

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US20240101710A1

公开(公告)日：2024-03-28

申请号：US18468854

申请日：2023-09-18

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Zea Melton ,  Tao Sai ,  Thomas John Van Blarcom

IPC: C07K16/42 ,  A61K49/00 ,  C07K1/22 ,  C07K16/28 ,  C12N5/0783 ,  G01N33/569

CPC classification number: C07K16/4266 ,  A61K49/0058 ,  C07K1/22 ,  C07K16/2878 ,  C12N5/0636 ,  G01N33/56972 ,  C07K2317/622 ,  C12N2501/998

Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BCMA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-BCMA CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

公开(公告)号：US12215347B2

公开(公告)日：2025-02-04

申请号：US17381693

申请日：2021-07-21

Applicant: Allogene Therapeutics, Inc.

Inventor： Michael Thomas Bethune ,  Yi Zhang ,  Thomas John Van Blarcom ,  Siler Panowski ,  Barbra Johnson Sasu

IPC: C12N5/0783 ,  A61K39/00 ,  C07K14/725 ,  C12N15/86

Abstract: Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and/or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.

公开(公告)号：US12036243B2

公开(公告)日：2024-07-16

申请号：US17183689

申请日：2021-02-24

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui Lin ,  Siler Panowski ,  Cesar Adolfo Sommer ,  Thomas John Van Blarcom ,  Barbra Johnson Sasu ,  Arun Balakumaran

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/715 ,  C07K16/28 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/7151 ,  C07K16/2878 ,  C12N15/86

Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.

公开(公告)号：US12104188B2

公开(公告)日：2024-10-01

申请号：US17716253

申请日：2022-04-08

Applicant: Allogene Therapeutics, Inc.

Inventor： Meritxell Galindo Casas ,  Thomas John Van Blarcom

IPC: C12N9/64 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/48 ,  A61K38/52 ,  C12N5/0783 ,  C12N9/90 ,  C12N11/18

CPC classification number: C12N9/6472 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/4873 ,  A61K38/52 ,  C12N5/0636 ,  C12N9/90 ,  C12N11/18 ,  C12Y304/22062 ,  C12Y502/01008 ,  C07K2319/50 ,  C07K2319/70 ,  C12N2501/734 ,  C12N2510/00 ,  C12N2740/16043

Abstract: Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.

公开(公告)号：US11786553B2

公开(公告)日：2023-10-17

申请号：US16804545

申请日：2020-02-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui Lin ,  Thomas John Van Blarcom ,  Siler Panowski ,  Barbra Johnson Sasu

IPC: C07K14/715 ,  C07K16/28 ,  C07K16/30 ,  A61K35/17 ,  C12N15/67 ,  A61K38/00

CPC classification number: A61K35/17 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/30 ,  C12N15/67 ,  A61K38/00 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74

Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

公开(公告)号：US12163169B2

公开(公告)日：2024-12-10

申请号：US16290388

申请日：2019-03-01

Applicant: Allogene Therapeutics, Inc.

Inventor： Andrew Ross Nager ,  Spencer Park ,  Javier Fernando Chaparro Riggers ,  Regina Junhui Lin ,  Thomas John Van Blarcom

IPC: C12N9/90 ,  A61K35/17 ,  A61K45/06 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K14/72 ,  C12N5/0783 ,  A61K38/00 ,  A61K48/00

Abstract: The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.

公开(公告)号：US12043655B2

公开(公告)日：2024-07-23

申请号：US16804917

申请日：2020-02-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui Lin ,  Thomas John Van Blarcom ,  Siler Panowski ,  Barbra Johnson Sasu

IPC: C07K14/715 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/86

CPC classification number: C07K14/715 ,  A61K35/17 ,  A61P35/00 ,  C07K16/40 ,  C12N5/0636 ,  C12N7/00 ,  C12N15/86 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2740/15043

Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.

公开(公告)号：US11326156B2

公开(公告)日：2022-05-10

申请号：US16177280

申请日：2018-10-31

Applicant: Allogene Therapeutics, Inc.

Inventor： Meritxell Galindo Casas ,  Thomas John Van Blarcom

IPC: C12N9/64 ,  C12N9/90 ,  A61K38/48 ,  A61K38/52 ,  A61K35/17 ,  C12N5/0783 ,  C12N11/18 ,  A61K31/7088

Abstract: Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.

公开(公告)号：US11814435B2

公开(公告)日：2023-11-14

申请号：US17005073

申请日：2020-08-27

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K31/454 ,  A61K31/704 ,  A61K31/69 ,  A61K47/68 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K31/454 ,  A61K31/69 ,  A61K31/704 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6801 ,  A61K47/6849 ,  C07K16/2803 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  A61K31/69 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.